98 related articles for article (PubMed ID: 29532488)
1. Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution.
Williams SM; Sumstad D; Kadidlo D; Curtsinger J; Luo X; Miller JS; McKenna DH
Transfusion; 2018 Jun; 58(6):1458-1467. PubMed ID: 29532488
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
Razmara AM; Farley LE; Harris RM; Judge SJ; Lammers M; Iranpur KR; Johnson EG; Dunai C; Murphy WJ; Brown CT; Rebhun RB; Kent MS; Canter RJ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631708
[TBL] [Abstract][Full Text] [Related]
3. Depletion of high-content CD14
Wang X; Borquez-Ojeda O; Stefanski J; Du F; Qu J; Chaudhari J; Thummar K; Zhu M; Shen LB; Hall M; Gautam P; Wang Y; Sénéchal B; Sikder D; Adusumilli PS; Brentjens RJ; Curran K; Geyer MB; Mailankhody S; O'Cearbhaill R; Park JH; Sauter C; Slovin S; Smith EL; Rivière I
Mol Ther Methods Clin Dev; 2021 Sep; 22():377-387. PubMed ID: 34514029
[TBL] [Abstract][Full Text] [Related]
4. Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing.
Noaks E; Peticone C; Kotsopoulou E; Bracewell DG
Mol Ther Methods Clin Dev; 2021 Mar; 20():675-687. PubMed ID: 33718517
[TBL] [Abstract][Full Text] [Related]
5. Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials.
Chatenoud L; Bach JF
Rev Diabet Stud; 2005; 2(3):116-20. PubMed ID: 17491686
[No Abstract] [Full Text] [Related]
6. How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?
Fernández L; Leivas A; Valentín J; Escudero A; Corral D; de Paz R; Vela M; Bueno D; Rodríguez R; Torres JM; Díaz-Almirón M; López-Collazo E; Martinez-Lopez J; Pérez-Martínez A
Transfusion; 2018 Jun; 58(6):1340-1347. PubMed ID: 29542132
[TBL] [Abstract][Full Text] [Related]
7. Advances in immunotherapy for acute myeloid leukemia.
Przespolewski A; Szeles A; Wang ES
Future Oncol; 2018 Apr; 14(10):963-978. PubMed ID: 29542352
[TBL] [Abstract][Full Text] [Related]
8. Editorial: Tailoring NK Cell Receptor-Ligand Interactions: An Art in Evolution.
Koehl U; Toubert A; Pittari G
Front Immunol; 2018; 9():351. PubMed ID: 29535727
[No Abstract] [Full Text] [Related]
9. Natural killer cells target and differentiate cancer stem-like cells/undifferentiated tumors: strategies to optimize their growth and expansion for effective cancer immunotherapy.
Kaur K; Nanut MP; Ko MW; Safaie T; Kos J; Jewett A
Curr Opin Immunol; 2018 Apr; 51():170-180. PubMed ID: 29653339
[TBL] [Abstract][Full Text] [Related]
10. Human Cytomegalovirus Infection Increases Both Antibody- and Non-Antibody-Dependent Cellular Reactivity by Natural Killer Cells.
Michelo CM; van Cranenbroek B; Touw P; Claas FHJ; van der Meer A; Joosten I
Transplant Direct; 2017 Dec; 3(12):e335. PubMed ID: 29536036
[TBL] [Abstract][Full Text] [Related]
11. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
Wagner J; Kline CL; Zhou L; Campbell KS; MacFarlane AW; Olszanski AJ; Cai KQ; Hensley HH; Ross EA; Ralff MD; Zloza A; Chesson CB; Newman JH; Kaufman H; Bertino J; Stein M; El-Deiry WS
J Clin Invest; 2018 Jun; 128(6):2325-2338. PubMed ID: 29533922
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia.
García-Muñoz R; Aguinaga L; Feliu J; Anton-Remirez J; Jorge-Del-Val L; Casajús-Navasal A; Nebot-Villacampa MJ; Daroca-Fernandez I; Domínguez-Garrido E; Rabasa P; Panizo C
Immunotherapy; 2018 Mar; 10(6):491-499. PubMed ID: 29562857
[TBL] [Abstract][Full Text] [Related]
13. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M; Arlen PM; Tsang KY
Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
[TBL] [Abstract][Full Text] [Related]
15. Process engineering of natural killer cell-based immunotherapy.
Motallebnejad P; Kantardjieff A; Cichocki F; Azarin SM; Hu WS
Trends Biotechnol; 2023 Oct; 41(10):1314-1326. PubMed ID: 37142447
[TBL] [Abstract][Full Text] [Related]
16. Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics.
Coyle KM; Hawke LG; Ormiston ML
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980629
[TBL] [Abstract][Full Text] [Related]
17. Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges.
Oh BLZ; Chan LWY; Chai LYA
Front Immunol; 2022; 13():1044946. PubMed ID: 36969979
[TBL] [Abstract][Full Text] [Related]
18. Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy.
Tarannum M; Romee R; Shapiro RM
Front Immunol; 2022; 13():859177. PubMed ID: 35401529
[TBL] [Abstract][Full Text] [Related]
19. Advances in NK cell production.
Fang F; Xie S; Chen M; Li Y; Yue J; Ma J; Shu X; He Y; Xiao W; Tian Z
Cell Mol Immunol; 2022 Apr; 19(4):460-481. PubMed ID: 34983953
[TBL] [Abstract][Full Text] [Related]
20. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
Front Immunol; 2021; 12():732135. PubMed ID: 34925314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
